Cargando…
Practical tools to identify short children born small-for-gestational-age eligible for rhGH treatment according to Italian regulation
Recombinant human growth hormone (rhGH) is an approved and effective treatment for short children born small for gestational age (SGA). Prevalence of children eligible for treatment as SGA is reported to be 1:1800. The latest data from the National Registry of Growth Hormone therapy (RNAOC) showed t...
Autores principales: | Tornese, Gianluca, Pricci, Flavia, Pellegrin, Maria Chiara, Villa, Marika, Rotondi, Daniela, Agazio, Elvira, Barbi, Egidio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805524/ https://www.ncbi.nlm.nih.gov/pubmed/31639023 http://dx.doi.org/10.1186/s13052-019-0715-x |
Ejemplares similares
-
The Italian Registry of GH Treatment: electronic Clinical Report Form (e-CRF) and web-based platform for the national database of GH prescriptions
por: Pricci, F., et al.
Publicado: (2018) -
Somatropin therapy in italian adults with growth hormone deficiency
por: Pricci, Flavia, et al.
Publicado: (2022) -
Noonan syndrome: rhGH treatment and
PTPN11
mutation
por: Wu, Xian, et al.
Publicado: (2023) -
GH Resistance Is a Component of Idiopathic Short Stature: Implications for rhGH Therapy
por: Savage, Martin O., et al.
Publicado: (2021) -
Safety of Pediatric rhGH Therapy: An Overview and the Need for Long-Term Surveillance
por: Cianfarani, Stefano
Publicado: (2021)